BPC-157 + TB-500 (10+10mg) · the classic recovery pairing
The ReferenceBenefits, protocols and preparationOpen the reference →The name Wolverine comes from the Marvel character because of his regenerative ability. This is what it does at the cellular level, translated into plain language.
10mg of BPC-157 works at the injury site: promotes angiogenesis (new blood vessels), modulates nitric oxide, and reduces local inflammation.
10mg of TB-500 facilitates the migration of repair cells throughout the body. If you have multiple or diffuse injuries, it reaches all of them.
Lowers TNF-α and IL-6 in animal models. Not yet measured in people.
Local repair + systemic cell migration. The blend itself has not been tested in trials.

Recover from an injury (tendon, joint)
WolverineRepairs tendon, ligament and muscle · Lowers inflammation
+ EnergyDriveMOTS-c+ Adds: More energy and physical performance
+ TesaFit+Tesamorelin+ Adds: Raises GH and IGF-1 physiologically
Wolverine + EnergyDriveWolverine + MOTS-cEnergyDrive (MOTS-c) adds: More energy and physical performance
Wolverine + TesaFit+Wolverine + TesamorelinTesaFit+ (Tesamorelin) adds: Raises GH and IGF-1 physiologically
Wolverine + AminoLeanWolverine + 5-Amino-1MQAminoLean (5-Amino-1MQ) adds: More energy and physical performanceWolverine combines the two most studied tissue repair peptides in research: BPC-157 (Body Protection Compound, a pentadecapeptide derived from human gastric juice) and TB-500 (a synthetic fragment of thymosin β-4). The blend's name comes from the Marvel character because of his regenerative ability.
SuperBio Labs Wolverine is supplied as pre-mixed lyophilized powder with HPLC purity ≥99% per component. Each batch ships with an independent Certificate of Analysis covering identity by LC-MS, peptide content (98–102% per component), endotoxin levels (<1.0 EU/mg), and solvent residues.
The dual local + systemic mechanism sets Wolverine apart. BPC-157 works at the injury site: it grows new vessels (via VEGFR2) and lowers local inflammation. TB-500 works body-wide, moving repair cells through actin regulation. Where the evidence stands, plainly: in people, BPC-157 has uncontrolled pilots (11 of 12 improved knee pain) and its first placebo-controlled trial began in 2026. Thymosin β4 (TB-500's parent protein) closed ulcers sooner in phase 2, not significantly. The blend itself has not been tested in trials: what adds up are two well-described research pathways.
Informed professional research use only.
Each order includes everything needed to use the full vial. No separate purchases required.
Lyophilized blend · BPC + TB · HPLC ≥99% · COA
Sterile solvent · 0.9% benzyl alcohol
21G needle · For reconstituting the blend
2-3 applications × 4 weeks
1 per application + 1 to reconstitute
Free app · Week-by-week protocol, product sheet and usage guide
8 steps · From opening the kit to first application
App · Cycle tracking · Human team 24/7
About the supplies: 12 syringes + 13 swabs cover a standard 4-week cycle (3×/wk). For longer cycles (up to 8 weeks), request extras — they are pharmacy supplies available over the counter in any city.
This product meets all five — your batch COA ships with the kit.
The official protocol included in the kit. If you have pre-existing medical conditions, consult a professional before starting.
Applying as close to the injury site as possible boosts BPC's local effect. For diffuse injuries or low-back areas you can't reach, TB-500's systemic effect has you covered.
Based on clinical literature from the Sikiric group (BPC) and TB-4 studies. Your experience may vary depending on injury severity and physiology.
Generally very well tolerated. Both components have one of the best safety profiles in this category. Common effects are minor and transient:
Occasional redness at the injection site (resolves in 10–30 min) · mild drowsiness in the first days (TB-500 effect on brain actin) · slight initial fatigue while the body adapts to the accelerated repair process.
Caution · angiogenesis: BPC-157 promotes the formation of new blood vessels. As a theoretical precaution, it is not recommended in people with active cancer or diagnosed tumors. To date, there are no studies showing promotion of tumor growth, but the caution is documented.
WADA: BPC-157 has been banned at all times, in and out of competition, since 2022 (S0). If you compete, do not use it.
Tendon, ligament or muscle · BPC-157 works on site; evidence mostly from animals.
TB-500 works body-wide: useful when more than one area hurts.
Knee · 11 of 12 improved with BPC-157 in an uncontrolled series.
Returning after an injury, alongside physical therapy and progressive load.
Thymosin β4 closed ulcers sooner in phase 2 · BPC-157 in models.
Active cancer or diagnosed tumor (grows new vessels) · if you compete (WADA).
| Components | BPC-157 10mg + TB-500 10mg |
| Total peptide | 20mg lyophilized |
| Purity (HPLC) | ≥99% per component |
| Format | Pre-mixed lyophilized powder |
| COA | Per batch · independent laboratory |
| Endotoxins | <1.0 EU/mg (LAL test) |
| Storage (unreconstituted) | 2–8 °C, protected from light · 24 months |
| Storage (reconstituted) | 60 days refrigerated (2–8°C) |
| Use | Use under professional judgment |